Oncology and Therapy

Scope & Guideline

Empowering global access to cutting-edge oncology research.

Introduction

Immerse yourself in the scholarly insights of Oncology and Therapy with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2366-1070
PublisherSPRINGER
Support Open AccessYes
CountrySwitzerland
TypeJournal
Converge2016, from 2018 to 2019, from 2021 to 2024
AbbreviationONCOL THER / Oncol. Ther.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES

Aims and Scopes

The journal 'Oncology and Therapy' focuses on advancing the understanding of cancer treatment and management through comprehensive research articles that encompass a wide range of topics related to oncology. It aims to bridge the gap between clinical practice and research by publishing studies that explore treatment patterns, patient experiences, and novel therapies.
  1. Real-World Evidence and Treatment Patterns:
    The journal consistently publishes studies that investigate real-world treatment patterns and outcomes across various cancer types, providing insights into how therapies are applied in everyday clinical settings.
  2. Patient-Centric Research:
    A strong emphasis is placed on understanding the patient experience and perspectives, including quality of life assessments and caregiver support, highlighting the importance of patient-relevant outcomes.
  3. Novel Therapeutics and Biomarkers:
    Research articles often explore innovative therapies, including targeted treatments, immunotherapies, and biomarker testing, contributing to the evolving landscape of personalized medicine in oncology.
  4. Health Economics and Cost-Effectiveness:
    The journal includes studies assessing the economic aspects of cancer treatment, evaluating cost-effectiveness, healthcare resource utilization, and economic burden on patients and healthcare systems.
  5. Multidisciplinary Approaches:
    Recognizing the complexity of cancer care, the journal promotes multidisciplinary research that integrates insights from medical oncology, surgery, radiology, and palliative care.
The journal 'Oncology and Therapy' has demonstrated an evolving focus on several emerging themes that reflect current trends in cancer research and treatment. These themes highlight the journal's responsiveness to advancements in the field and the changing landscape of oncology.
  1. Immunotherapy and Targeted Therapies:
    There is a growing emphasis on research surrounding immunotherapies and targeted therapies, reflecting the shift towards personalized medicine and the increasing importance of genetic and molecular profiling in treatment decisions.
  2. Patient Experience and Shared Decision-Making:
    Emerging themes include the exploration of patient experience and shared decision-making processes, underscoring the importance of incorporating patient perspectives into treatment planning and management.
  3. Real-World Data Utilization:
    The use of real-world data to inform treatment patterns and outcomes is increasingly highlighted, showcasing the journal's commitment to understanding how therapies perform outside controlled clinical trial settings.
  4. Integration of Palliative Care:
    There is a notable trend towards integrating palliative care into oncology treatment plans, emphasizing holistic approaches to cancer care that address both curative and supportive needs of patients.
  5. Health Equity and Access to Care:
    Recent articles are beginning to address health equity and access to cancer care, focusing on disparities in treatment and outcomes among different populations, which is becoming a critical area of research.

Declining or Waning

While 'Oncology and Therapy' continues to thrive in several key areas, some themes have shown a decline in focus over recent years. This shift may reflect changes in research priorities or the maturation of certain fields within oncology.
  1. Traditional Chemotherapy Focus:
    There has been a noticeable decrease in articles centered on traditional chemotherapy regimens as newer, more targeted therapies gain prevalence in clinical practice and research.
  2. Generalized Cancer Treatment Strategies:
    The journal has shifted away from broad, generalized treatment strategies in favor of more specific and nuanced approaches, indicating a move towards personalized and tailored treatment plans.
  3. Basic Cancer Biology Studies:
    Research focused solely on basic cancer biology without direct clinical application has become less prominent, as the journal prioritizes studies that offer direct implications for patient care and treatment.

Similar Journals

European Urology Oncology

Delivering high-quality, peer-reviewed content for medical excellence.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Targeted Oncology

Connecting breakthroughs with clinical applications.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

World Journal of Clinical Oncology

Empowering Oncology with Cutting-Edge Insights
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Elevating Cancer Research to New Heights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

Oncology Letters

Pioneering Research for a Brighter Future in Oncology
Publisher: SPANDIDOS PUBL LTDISSN: 1792-1074Frequency: 12 issues/year

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

JCO Precision Oncology

Advancing Personalized Medicine for Better Outcomes
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Oncology in Clinical Practice

Navigating the Landscape of Cancer Treatment
Publisher: VIA MEDICAISSN: 2450-1654Frequency: 6 issues/year

Oncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.

SURGICAL ONCOLOGY-OXFORD

Innovating oncology surgery through comprehensive peer-reviewed studies.
Publisher: ELSEVIER SCI LTDISSN: 0960-7404Frequency: 4 issues/year

Surgical Oncology-Oxford is a prestigious academic journal published by Elsevier Science Ltd, dedicated to advancing the field of surgical oncology. Since its establishment in 1992, the journal has provided a vital platform for disseminating cutting-edge research, clinical advancements, and innovative surgical techniques. With a focus on both surgery and oncology, the journal is ranked in the Q2 category in Surgery and Q3 in Oncology for 2023, reflecting its commitment to quality and impactful contributions. It ranks #107 out of 551 in Medicine_Surgery and #184 out of 404 in Medicine_Oncology as per Scopus metrics, illustrating its significant role in the academic landscape. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that only the highest quality research is published. By examining the latest surgical methodologies and oncological insights, Surgical Oncology-Oxford plays a crucial role in enhancing clinical practice and improving patient outcomes, making it an essential resource for researchers, healthcare professionals, and students aiming to stay at the forefront of the field.

Nature Reviews Clinical Oncology

Exploring Breakthroughs in Clinical Oncology
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Clinical Genitourinary Cancer

Innovating research for a healthier tomorrow.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.